Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 3Advanced Solid Tumor 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Breast Neoplasms 2Pancreatic Neoplasms 1Neuroendocrine Tumors 1Major Advanced Solid Tumors Other Than Colorectal 1Lung Neoplasms 1Leukemia 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1ADVANCED SOLID TUMORS 1

Interventions

Injections 18Carboplatin 14Docetaxel 11pembrolizumab 8durvalumab 7Cisplatin 6linifanib 5Paclitaxel 5Nivolumab 5zimberelimab 4talazoparib 4olaparib 4Panobinostat 4Itraconazole 4Bevacizumab 4tremelimumab 3sintilimab 3depatuxizumab 3atezolizumab 3ST 1481 3S 1 (combination) 3Rifampin 3Pemetrexed 3Oxaliplatin 3Fluorouracil 3Everolimus 3Drug Therapy 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors × PM 01183 × Clear all
NCT05063318 2025-09-02

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

PharmaMar

Phase 1 Completed
14 enrolled 20 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡